Hims challenges Novo Nordisk with affordable weight-loss pill launch

Hims & Hers Health, Inc. HIMS has launched a $49 compounded version of the oral Wegovy weight-loss pill, a move that directly undercuts the $199 price set by Novo Nordisk A/S NVO. The introduction of this lower-priced alternative on February 5, 2026, has immediately created significant pricing pressure in the GLP-1 weight-loss market within the United States US.

The market reaction was swift and impactful, as shares of Novo Nordisk A/S NVO fell 8.6% following the news. Eli Lilly and Company LLY also experienced a sharp decline, with its shares dropping 6%. This sector-level volatility reflects investor concerns over the competitive landscape for weight-loss treatments as compounded versions enter the market at a fraction of the cost of branded drugs produced by companies in the United States US and Denmark DK.